Ocugen, Inc.
OCGN
Rank in Stocks
#14348
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase,... Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Share Price
$0.9721
Last synced: 2026-11-09
Market Cap
$329.65M
Change (1 day)
5.09%
Change (1 year)
-26.91%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ocugen, Inc. (OCGN)
Category
Healthcare
Operating Margin for Ocugen, Inc. (OCGN)
Operating Margin as of November 2026 TTM: -1,504.43%
According to Ocugen, Inc.'s latest financial reports, its current operating margin (TTM) is -1,504.43%. At the end of 2025 the company had an operating margin of -1,425.70%.
Operating Margin history for Ocugen, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,504.43% | 5.52% |
| 2025 | -1,425.70% | 5.58% |
| 2024 | -1,350.36% | 24.38% |
| 2023 | -1,085.67% | -69.67% |
| 2022 | -3,580.02% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -49,500.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -210,562.50% | 265.76% |
| 2012 | -57,569.23% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.03% |
US
|
|
| -149.01% | -99.90% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ocugen, Inc.'s operating margin
What is Ocugen, Inc.'s operating margin?
Ocugen, Inc.'s operating margin is -1,504.43%, as of Nov 2026.
What was Ocugen, Inc.'s operating margin in 2025?
In 2025, Ocugen, Inc.'s operating margin was -1,425.70%, compared with -1,350.36% in 2024.
How has Ocugen, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Ocugen, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2020 (-49,500.00%).
How does Ocugen, Inc.'s operating margin compare with similar companies?
Ocugen, Inc.'s operating margin (-1,504.43%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.